CompletedPhase 2NCT02828358
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Studying Acute leukemia of ambiguous lineage
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Rishi S KotechaChildren's Oncology Group
- Intervention
- Azacitidine(drug)
- Enrollment
- 78 enrolled
- Eligibility
- All sexes
- Timeline
- 2017 – 2024
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- USA Health Strada Patient Care Center, Mobile, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Banner Children's at Desert, Mesa, Arizona, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02828358 on ClinicalTrials.govOther trials for Acute leukemia of ambiguous lineage
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07046078Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT06317662Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06013423Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesFred Hutchinson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT05761171A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaChildren's Oncology Group
- RECRUITINGPHASE2NCT05901974Venetoclax Combined With Azactidine in the Treatment of ALALSheng-Li Xue, MD
- RECRUITINGPHASE2NCT05735717MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesMasonic Cancer Center, University of Minnesota
- ACTIVE NOT RECRUITINGPHASE1NCT04898894Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT04099966AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionMitchell Cairo